Busca avançada
Ano de início
Entree


Assessment of Renal Function in Head and Neck Cancer Patients Treated with Cisplatin: Different Biomarkers and Acute Kidney Injury Classifications

Texto completo
Autor(es):
de Godoy Torso, Nadine ; Visacri, Marilia Berlofa ; Quintanilha, Julia Coelho Franca ; Cursino, Maria Aparecida ; Pincinato, Eder de Carvalho ; Moriel, Patricia
Número total de Autores: 6
Tipo de documento: Artigo Científico
Fonte: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; v. 24, n. 1, p. 18-pg., 2023-01-01.
Resumo

Cisplatin is associated with dose-limiting nephrotoxicity, and the timely detection of acute kidney injury (AKI) can affect morbimortality. Therefore, this study aimed to investigate the tools for monitoring renal function in AKI. This was a retrospective, cohort study. Cisplatin-treated patients with head and neck cancer were included. Nephrotoxicity was assessed using serum creatinine, estimated creatinine clearance, serum electrolytic alterations, and plasma kidney injury molecule-1 (KIM-1). The toxicity severity was classified according to Common Terminology Criteria for Adverse Events (CTCAE), and AKI was classified by Risk, Injury, Failure, Loss, and End-stage kidney disease (RIFLE) and Acute Kidney Injury Network (AKIN). A total of 81 participants were included, of whom only 32 did not have AKI. Almost 90% of participants had a decreased estimated glomerular filtration rate five (D5) days after chemotherapy. The AKI estimate differs between AKIN and RIFLE; more participants were diagnosed by the RIFLE at D5, 19.5% versus 2.4% by AKIN, and fifteen had a discordance between these classifications. All laboratory markers showed significant changes on D5. KIM-1 appeared a possible biomarker when considering CTCAE or AKIN classifications (p < 0.05 on D5), but not when RIFLE classification was used (p = 0.0780). Further studies may seek to understand the profiles of different biomarkers together. (AU)

Processo FAPESP: 19/20010-7 - MicroRNAs como possíveis preditores de nefrotoxicidade induzida pela cisplatina em pacientes com câncer de cabeça e pescoço
Beneficiário:Nadine de Godoy Torso
Modalidade de apoio: Bolsas no Brasil - Mestrado
Processo FAPESP: 17/17245-7 - Análise do polimorfismo dos genes CYP2E1, ABCB1, ABCC2, OCT2 e MATE1 envolvidos nos principais efeitos adversos do tratamento de Câncer de Cabeça e Pescoço com cisplatina
Beneficiário:Maria Aparecida Cursino
Modalidade de apoio: Bolsas no Brasil - Doutorado
Processo FAPESP: 17/02338-0 - MicroRNAs e biomoléculas oxidadas como possíveis biomarcadores de nefrotoxicidade induzida pela cisplatina em pacientes com câncer de cabeça e pescoço
Beneficiário:Júlia Coelho França Quintanilha
Modalidade de apoio: Bolsas no Brasil - Doutorado